Tumor heterogeneity, the diverging evolution of both different subparts of primary tumors and of metastases compared to the primary tumor, is often named among the challenges for targeted treatment.more »
LONDON A $1 billion program to develop vaccines against emerging infectious diseases that, like Zika and Ebola viruses, have the potential to cause serious epidemics, will be launched at the World Economic Forum in Davos, Switzerland.more »
DUBLIN – Forward Pharma A/S is banking a $1.25 billion cash payment from Biogen Inc. in a partial settlement of their intellectual property dispute over the use of dimethyl fumarate for treating multiple sclerosis, and it could also be in line to pocket future royalties from sales of Biogen's Tecfidera product.
- Trulance joins dance in CIC; Linzess still charms as Wall Street mulls duel in market
- AZ advances creative China strategy as IL-6 antibody green-lighted
- Industry: Proposals to IP regime in Australia would harm innovation
- Celltrion: FDA's new biosimilar guidelines 'good news for us'
- Taking big step in ADCs, South Korea's Legochem ...
Biotech investors live on their nerves these days and it doesn't take much for them to head for the hills on any negative news. Recall a tweet last September from presidential candidate Hillary Clinton, which essentially said she would take on the issue of rising drug prices. That served to tank the biotech sector, which lost more than 5 percent in value in one day. Although it took a couple of months, the industry did recover and get back to its original pre-tweet level.
"Basically, it's not easy to define what will serve humanity."
So said Yoshinori Ohsumi, honorary professor at the Tokyo Institute of Technology, after winning the 2012 Kyoto Prize in Life Sciences for his research.
The Nobel Assembly followed suit in recognizing the importance of Ohsumi's work, awarding him the 2016 Nobel Prize in Physiology or Medicine to "for his discoveries of mechanisms for autophagy."READ MORE »
- New targets for overcoming melanoma resistance identified »
- Dual-action, dual-indication decoy fights tumors, viruses »
- Stem cell-based model suggests deafness treatments »
- Stabilizing MLL fights fusion proteins' effects »
- Platelet activation blocker affects clotting more than bleeding »
- Stem cell strategy boosts testosterone »
- Depressed patients are less responsive to chemotherapy »
- Ribociclib ups survival in postmenopausal Asian women with advanced breast cancer »
- CRISPR goes massively multiplex, further expanding reach »
- Yes, there’s a doctor in the House (and Senate)January 04, 2017 | 12:21 AM | Posted by: Mari Serebrov
- Time for fa-la-la with BioWorld’s 10th annual Holiday Gift GuideDecember 02, 2016 | 8:43 PM | Posted by: Marie Powers
- Biotech’s biggest protesters are turning into its supporters November 30, 2016 | 10:58 PM | Posted by: Amanda Lanier
- Sex and drugs: Something doesn’t ‘Addyi’ upNovember 04, 2016 | 10:35 PM | Posted by: Randy Osborne
- Rules of the PAP road not always clear, even to seasoned travelersOctober 25, 2016 | 11:37 PM | Posted by: Marie Powers
Partners in Focus
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST